Austar Lifesciences (6118) Fundamentals 2026 — P/E 9.2x, Revenue Analysis | SniperIQ
Austar Lifesciences (6118) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of HK
Austar Lifesciences (6118) has a market capitalization of approximately HK
Austar Lifesciences's trailing twelve-month P/E ratio is 9.2x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Austar Lifesciences runs a net profit margin of 2.2%, a gross margin of 19.2%, and an operating margin of 3.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Austar Lifesciences reported revenue of ¥1.5B for fiscal year 2025, with net income of ¥34M and earnings per share (EPS) of 0.066. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Austar Lifesciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Austar Lifesciences carries a debt-to-equity ratio of 0.42x and a current ratio of 1.36x, with a market beta of 0.89. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Austar Lifesciences (6118) the key facts are: market cap HK
Get Austar Lifesciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.